LYEL

Lyell Immunopharma, Inc.

SEC CIK 1806952
$13.72 −46.8% · 90 days
90-day buys
$0
0 open-market
90-day sells
$25K
1 open-market
Net insider flow
−$25K
Net selling
Filings shown
28
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at LYEL have sold a net $25K of stock (0 open-market buys vs 1 sell).

Largest recent trade: Arch Venture Partners Ix, Llc, LYEL's 10% owner, spent $12.5M of their own money on 488,090 shares at $26, growing their stake 52%.

Most active filer: Seely Lynn, with 6 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for LYEL, newest first
View on SEC EDGAR ↗
LYEL
Sell Shook David · Chief Medical Officer · Open-market sale · filed 1d ago ΔOwn −8.6%

Shook David sold $25K of LYEL, trimming their stake 9%.

−$25K
1,977 sh @ $13
LYEL
Buy ARCH Venture Partners IX, LLC · 10% Owner · Open-market purchase · filed Mar 9, 2026 ΔOwn +52%

Arch Venture Partners Ix, Llc, LYEL's 10% owner, spent $12.5M of their own money on 488,090 shares at $26, growing their stake 52%.

+$12.5M
488,090 sh @ $26
LYEL
Buy ARCH Venture Fund XIII, L.P. · 10% Owner · Open-market purchase · filed Mar 9, 2026 ΔOwn +52%

Arch Venture Fund Xiii, L.p., LYEL's 10% owner, spent $12.5M of their own money on 488,090 shares at $26, growing their stake 52%.

+$12.5M
488,090 sh @ $26
LYEL
Sell Seely Lynn · Director, President and CEO · Open-market sale · filed Feb 12, 2026 ΔOwn −9.1%

Seely Lynn sold $174.4K of LYEL, trimming their stake 9%.

−$174.4K
7,455 sh @ $23
LYEL
Sell Hill Stephen J. · Chief Operating Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −6.5%

Hill Stephen J. sold $28.9K of LYEL, trimming their stake 6%.

−$28.9K
1,236 sh @ $23
Advertisement
LYEL
Sell Lee Gary K. · Chief Scientific Officer · Open-market sale · filed Feb 12, 2026 ΔOwn −9.0%

Lee Gary K. sold $39.1K of LYEL, trimming their stake 9%.

−$39.1K
1,671 sh @ $23
LYEL
Sell Hill Stephen J. · Chief Operating Officer · Open-market sale · filed Feb 11, 2026 ΔOwn −0.6%

Hill Stephen J. sold $2.5K of LYEL, trimming their stake 1%.

−$2.5K
109 sh @ $23
LYEL
Sell Lee Gary K. · Chief Scientific Officer · Open-market sale · filed Feb 11, 2026 ΔOwn −0.8%

Lee Gary K. sold $3.4K of LYEL, trimming their stake 1%.

−$3.4K
147 sh @ $23
LYEL
Sell Seely Lynn · Director, President and CEO · Open-market sale · filed Feb 11, 2026 ΔOwn −0.5%

Seely Lynn sold $10.1K of LYEL, trimming their stake 1%.

−$10.1K
438 sh @ $23
LYEL
Sell Bulis Veronica Sanchez · VP, Corporate Controller · Open-market sale · filed Feb 11, 2026 ΔOwn −1.6%

Bulis Veronica Sanchez sold $5.9K of LYEL, trimming their stake 2%.

−$5.9K
254 sh @ $23
LYEL
Sell Bulis Veronica Sanchez · VP, Corporate Controller · Open-market sale · filed Jan 6, 2026 ΔOwn −12%

Bulis Veronica Sanchez sold $30.3K of LYEL, trimming their stake 12%.

−$30.3K
936 sh @ $32
LYEL
Sell Bulis Veronica Sanchez · VP, Corporate Controller · Open-market sale · filed Jan 6, 2026 ΔOwn −12%

Bulis Veronica Sanchez sold $43.9K of LYEL, trimming their stake 12%.

−$43.9K
1,136 sh @ $39
LYEL
Sell Seely Lynn · Director, President and CEO · Open-market sale · filed Nov 12, 2025 ΔOwn −0.6%

Seely Lynn sold $6.6K of LYEL, trimming their stake 1%.

−$6.6K
412 sh @ $16
LYEL
Sell Bulis Veronica Sanchez · VP, Corporate Controller · Open-market sale · filed Nov 12, 2025 ΔOwn −2.5%

Bulis Veronica Sanchez sold $3.8K of LYEL, trimming their stake 3%.

−$3.8K
239 sh @ $16
LYEL
Sell Lee Gary K. · Chief Scientific Officer · Open-market sale · filed Nov 12, 2025 ΔOwn −0.9%

Lee Gary K. sold $2.2K of LYEL, trimming their stake 1%.

−$2.2K
138 sh @ $16
LYEL
Sell Hill Stephen J. · Chief Operating Officer · Open-market sale · filed Nov 12, 2025 ΔOwn −0.6%

Hill Stephen J. sold $1.5K of LYEL, trimming their stake 1%.

−$1.5K
95 sh @ $16
LYEL
Sell Seely Lynn · Director, President and CEO · Open-market sale · filed Aug 22, 2025 ΔOwn −9.7%

Seely Lynn sold $76.5K of LYEL, trimming their stake 10%.

−$76.5K
7,257 sh @ $11
LYEL
Sell Hill Stephen J. · Chief Operating Officer · Open-market sale · filed Aug 22, 2025 ΔOwn −6.0%

Hill Stephen J. sold $10.6K of LYEL, trimming their stake 6%.

−$10.6K
1,004 sh @ $11
LYEL
Sell Newton Charles W. · Chief Financial Officer · Open-market sale · filed Aug 22, 2025 ΔOwn −8.7%

Newton Charles W. sold $15.3K of LYEL, trimming their stake 9%.

−$15.3K
1,453 sh @ $11
LYEL
Sell Lee Gary K. · Chief Scientific Officer · Open-market sale · filed Aug 22, 2025 ΔOwn −8.6%

Lee Gary K. sold $15.3K of LYEL, trimming their stake 9%.

−$15.3K
1,453 sh @ $11
Advertisement

About LYEL insider activity

This page tracks every recent Form 4 filed for Lyell Immunopharma, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is LYEL insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Lyell Immunopharma, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.